Overview

We have considered as examples for the proof of principle two different diseases that could be treated by the use of our synthetic microencapsulated cellular device (Figure 1):

• The therapy of hepatitis C by the local production of interferon alpha followed by the production of hepatocyte growth factor, providing a regeneration step.
• The therapy of ischaemic heart disease with anakinra as an antiinflammatory agent, while vascular endothelial growth factor and platelet-derived growth factor, produced in stoichiometric amounts enhance angiogenesis and tissue oxigenation.